Phase 2 Coeliac Disease Trial, Recruiting NCT07239336 Sponsor: Chugai Pharmaceutical Condition: Coeliac Disease
Back to Coeliac Disease

Phase 2 Coeliac Disease Trial, Recruiting

NCT07239336
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your body mass index (BMI) must be between 18 and 40 at the time of your screening appointment.
  • You must be willing to eat a gluten-free product and specially prepared products that simulate accidental gluten exposure as part of the study.
  • You must have been formally diagnosed with celiac disease by a doctor, with that diagnosis recorded in your medical records.
  • You must have been following a gluten-free diet for at least 12 months before your screening appointment, and must be willing to continue that same diet throughout the study.
  • A blood test must confirm that you carry a specific genetic marker called HLA DQ2.5 (confirm with trial site).
  • You must have experienced at least 2 gluten-related symptom episodes in the month before screening — these symptoms include diarrhea, stomach pain, bloating, nausea, or tiredness.
  • You must be willing to have 2 internal camera examinations of your upper digestive tract (called endoscopies), which include taking small tissue samples from your small intestine.
  • A tissue sample must show that there is still ongoing damage to the lining of your small intestine (confirm with trial site).

Who may not be able to join:

  • You may not be eligible if you have been diagnosed with, or are suspected to have, a more severe form of celiac disease called Refractory Celiac Disease.
  • You may not be eligible if you have a history of allergic reactions triggered by wheat, barley, rye, or certain ingredients used in the study products such as methylcellulose or gelatin.
  • You may not be eligible if you have been diagnosed with cancer, including blood cancers or solid tumours, within the past 5 years, or if you have ever been diagnosed with T cell or B cell lymphoma.
  • You may not be eligible if you have had a serious allergic reaction (including anaphylaxis) to a biological medicine or any of its ingredients.
  • You may not be eligible if your genetic test shows you carry a different genetic marker called HLA-DQ8 (confirm with trial site).
  • You may not be eligible if you have any other ongoing digestive condition — such as inflammatory bowel disease, irritable bowel syndrome, or acid reflux — that could affect the study results.
  • You may not be eligible if tests show you currently have a stomach infection called Helicobacter pylori.
  • You may not be eligible if your screening blood test is positive for HIV.
  • You may not be eligible if your screening blood test shows signs of a current hepatitis B infection.
  • You may not be eligible if your screening blood test is positive for hepatitis C, unless a follow-up test confirms the virus is not active in your body.
  • You may not be eligible if a specific test shows you have active tuberculosis (TB) at the time of screening.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Chugai Pharmaceutical Co., Ltd., clinical-trials@chugai-pharm.co.jp

Phone: only use Email

Australian sites

Sydney Clinical Trials Pty Ltd, Campbelltown, New South Wales
University of the Sunshine Coast Clinical Trials Centre, Morayfield, Queensland
University of The Sunshine Coast Clinical Trials Centre (Sippy Downs), Sippy Downs, Queensland
Mater, South Brisbane, Queensland
University of the Sunshine Coast Clinical Trials Centre (SouthBank), South Brisbane, Queensland

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Chugai Pharmaceutical
Registry
ClinicalTrials.gov
Start date
16 December 2025
Est. completion
15 June 2027

Where this trial is recruiting

🇦🇺 Australia 🇳🇿 New Zealand 🇺🇸 United States

5 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Change in Villous Height to Crypt Depth Ratio (Vh:Cd)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov